Synairgen plc’s (LON:SNG) prelims revealed the company made significant progress in the year just gone.
It completed the first part of its SG015 study, assessing the safety of its inhaled interferon beta drug, SNG001.
The second instalment of the phase II trial is currently underway at 13 separate sites.
SNG001 is being developed for people suffering COPD, also known as smokers’ lung, who have cold or flu infections.
The company’s Australian partner, meanwhile, completed phase I trials and toxicology on a LOXL2 inhibitor developed by Synairgen.
This now paves the way for Pharmaxis to advance discussions with potential partners for the drug, which has been developed to treat non-alcoholic liver disease and a rare lung condition.
Financially, the company ended last year with £5.33mln in the bank, having raised £2.7mln.
Research and development costs were £3.23mln, while the company posted a loss of £4.13mln.